Cargando…

Metalloproteinase inhibitors as a potential therapeutic approach in multiple myeloma: a preliminary study

Detalles Bibliográficos
Autores principales:	Pais, A Sofia, Gonçalves, A Cristina, Geraldes, Catarina, Nascimento-Costa, José M, Sarmento-Ribeiro, Ana B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255049/

Ejemplares similares

P841: MOLECULAR MECHANISMS OF RESISTANCE TO IMMUNOMODULATORS IN MULTIPLE MYELOMA: AN IN VITRO STUDY
por: Alves, Raquel, et al.
Publicado: (2023)

P1358: WILL COVID-19 PANDEMIC CHANGE MOBILIZATION STRATEGY OF HEMATOPOIETIC STEM CELLS IN MULTIPLE MYELOMA PATIENTS FOR THE BETTER?
por: Marques, B., et al.
Publicado: (2022)

Delocalized lipophilic cations as a new therapeutic approach in cancer
por: Ribeiro, A Barbosa, et al.
Publicado: (2010)

New targeted therapies in myelodysplastic syndrome: the role of farnesyltransferase and proteasome inhibitors
por: Gonçalves, A Cristina, et al.
Publicado: (2010)

The role of CD26 and CD40 expression in therapeutic response - experimental study in oral cancer lines
por: Batista, Joana PN, et al.
Publicado: (2010)

Antitumoral effect of farnesiltransferase and mtor inhibitors in hepatocellular carcinoma: in vitro studies
por: Araújo, Ana M, et al.
Publicado: (2010)

Recombinant trail: a synergistic effect in myeloid leukemias
por: Carvalho, Filipa, et al.
Publicado: (2010)

P900: SALVAGE AUTOLOGOUS STEM CELL TRANSPLANT IN RELAPSED MULTIPLE MYELOMA: A SINGLE CENTRE EXPERIENCE
por: Duarte, S., et al.
Publicado: (2022)

Genome-wide nucleosome mapping in multiple myeloma
por: Small, Eliza C, et al.
Publicado: (2013)

Histone deacetylation - a new epigenetic target in cancer
por: Carvalho, João A, et al.
Publicado: (2010)

Serum pro-metalloproteinase 9 is a predictor of length of ICU and hospital stay in patients with septic shock
por: Costa, NA, et al.
Publicado: (2013)

Healthcare-associated infection: do doctors recognize this group of patients?
por: Cardoso, T, et al.
Publicado: (2011)

Matrix metalloproteinases and tissue inhibitors in multiple myeloma: promote or inhibit?
por: Li, Yan-Ying, et al.
Publicado: (2023)

P01.15. Multiple Myeloma, chemotherapy and curcumin
por: Panutich, E, et al.
Publicado: (2012)

Extending the classification of healthcare-associated bloodstream infection to other main foci: respiratory, urinary and intra-abdominal
por: Cardoso, C, et al.
Publicado: (2011)

P659: BUPARLISIB A PROMISING THERAPEUTIC APPROACH IN CHRONIC MYELOID LEUKEMIA RESISTANT TO IMATINIB
por: Alves, Raquel, et al.
Publicado: (2023)

Liver disease progression in HIV/HCV co-infected patients: a role for metalloproteinases and their specific inhibitors
por: Sasongko, Priyo
Publicado: (2006)

Evaluation of the role of mir-34b in modulation of radioresistance in non-small cell lung cancer
por: Silva, Joana B, et al.
Publicado: (2010)

MDR modulation in colorectal adenocarcinoma cell lines: kinetic studies using (99m)Tc-sestamibi
por: Casalta-Lopes, João, et al.
Publicado: (2010)

Cytogenetic and interphase Fluorescence in Situ Hybridization studies in patients with multiple myeloma
por: Perumal, G, et al.
Publicado: (2014)

AJAK inhibitor, tofacitinibreduces IL-6 and matrix metalloproteinase-3 productionin rheumatoid arthritis with suppressed cartilage destruction
por: Yamaoka, Kunihiro, et al.
Publicado: (2012)

Serum imbalance between the extracellular matrix metalloproteinases (MMP-2 and MMP-9) and their tissue inhibitor (TIMP-1) in patients with food and airborne allergy
por: Kuźmiński, A, et al.
Publicado: (2013)

Multiple Myeloma in Portugal: Burden of Disease and Cost of Illness
por: Neves, Manuel, et al.
Publicado: (2021)

Therapeutic drug monitoring of meropenem and piperacilin administered in continuous infusion. preliminary data
por: Miralbés Torner, M, et al.
Publicado: (2015)

P-149: Immunogenicity of SARS-CoV-2 vaccine in patients with multiple myeloma
por: Malard, Florent, et al.
Publicado: (2021)

Impact of pro-domain stability of matrix metalloproteinase-8 on the outcome of sepsis
por: McLaughlin, J, et al.
Publicado: (2011)

P033. Headache and commuting: preliminary data in a group of workers
por: Pucci, Ennio, et al.
Publicado: (2015)

Preclinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
por: Drent, Esther, et al.
Publicado: (2015)

P-160: Disparities in multiple myeloma between hispanics and non-hispanics – real world outcomes
por: Shaikh, Hira, et al.
Publicado: (2022)

An imaging review of extramedullary myeloma
por: Kay, M, et al.
Publicado: (2015)

Matrix metalloproteinase-8 is a regulator of the clinical aggressiveness of mammary tumours
por: Pennington, CJ, et al.
Publicado: (2008)

P912: COVID19 SEVERITY AND THERAPEUTIC OPTIONS IN PATIENTS WITH MULTIPLE MYELOMA
por: Karimova, E., et al.
Publicado: (2022)

P833: MARCH5 AS A POTENTIAL THERAPEUTIC TARGET IN MULTIPLE MYELOMA
por: Bashiri, Hamed, et al.
Publicado: (2023)

P805: EXTRAMEDULLARY MULTIPLE MYELOMA: MOLECULAR PATHOGENESIS AND NOVEL THERAPEUTIC TARGETS
por: Zihala, David, et al.
Publicado: (2023)

Serial change of C1 inhibitor in patients with sepsis: a preliminary report
por: Hirose, T, et al.
Publicado: (2015)

Parthenolide Induces ROS-Mediated Apoptosis in Lymphoid Malignancies
por: Jorge, Joana, et al.
Publicado: (2023)

Determination of strain pattern in patients with cardiac amyloidosis secondary to Multiple myeloma: a feature tracking study
por: Bhatti, Sabha, et al.
Publicado: (2016)

ADAMTS15 metalloproteinase inhibits breast cancer cell migration
por: Wagstaff, L, et al.
Publicado: (2010)

Genomic variations within matrix metalloproteinase-9 and severe sepsis
por: Chen, Q, et al.
Publicado: (2009)

Alveolar Recruitment for ARDS Trial: preliminary results
por: Cavalcanti, AB, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_j6s65km08ev0kn8k7i9g5cjmj3